miR‑876‑5p suppresses breast cancer progression through targeting TFAP2A

Xu, Jie; Zheng, Jie; Wang, Jian; Shao, Junfeng

doi:10.3892/etm.2019.7689

Cited by 26 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we tested miR-876 expression in HCC cells and clinical tissues and confirmed its antitumor roles in HCC. Our results are consistent with numerous studies of miR-876 in other tumors, such as breast cancer, lung cancer, cholangiocarcinoma, osteosarcoma, and gastric cancer [ 34 – 38 ]. The roles of miR-876 seem to be diverse in different kinds of tumors.…”

Section: Discussionsupporting

confidence: 93%

miR‐876 Inhibits EMT and Liver Fibrosis via POSTN to Suppress Metastasis in Hepatocellular Carcinoma

Chen

Zhang³

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. The asymptomatic onset, frequent recurrence, and poor prognosis of hepatocellular carcinoma (HCC) prompted us to identify new therapeutic targets or predictive markers of HCC diagnosis or prognosis. Methods. In this study, bioinformatics analysis was used to screen for target miRNAs from the open-access TCGA database. Transwell assays, Western blotting, and qRT-PCR analyses were used to detect cellular functions and gene expression in HCC cells and samples. A nude mouse tumorigenesis model was established to facilitate the observation of HCC progression. Other assays included luciferase reporter assays, IHC, and survival analysis. Results. We found that the identified miR-876 from TCGA was expressed at low levels in HCC cell lines and that low miR-876 expression was corrected with liver cirrhosis, tumor thrombus, and TNM stage. Further research revealed that miR-876 regulated cell invasion, EMT, and collagen expression by targeting POSTN expression. miR-876 and POSTN were inversely correlated in HCC samples and associated with EMT status and liver fibrosis in clinical HCC tissues. miR-876 inhibited the liver cancer progression in in vivo animal assays. Finally, both miR-876 and POSTN were risk factors for HCC survival, and HCC patients with combined low miR-876 and high POSTN expression had worse prognosis. Conclusions. miR-876 inhibited HCC EMT and fibrosis by targeting POSTN, thus affecting HCC progression and prognosis. miR-876 and POSTN may be useful therapeutic targets or prognostic markers of HCC.

show abstract

Section: Discussionsupporting

confidence: 93%

miR‐876 Inhibits EMT and Liver Fibrosis via POSTN to Suppress Metastasis in Hepatocellular Carcinoma

Chen

Zhang³

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…MiR-487a-3p serves as a tumor suppressor in prostate cancer by targeting CCND1 (cyclin D1, CCND1) [ 33 ]. MiR-876-5p has been validate as a tumor suppressor in multiple tumors including breast cancer, gastric cancer, colorectal cancer, head and neck squamous cell carcinoma, liver cancer and so on [ 16 , 17 , 34 – 36 ], and its downstream targets includes TFAP2A, MITF, RASAL2, vimentin, DNMT3A and so on [ 16 , 17 , 34 – 36 ]. In this study, for the first time, we found that miR-876-5p was remarkably down-regulated in PCa tissues and cells, and could inhibit the proliferation of PCa cells.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, numerous research has shown that miRNAs are involved in the progression of many tumors, and the abnormal expression profile of miRNAs is also related to PCa [14,15]. MiR-876-5p origins from the precursor RNA transcribed from human chromosome 9p21.1, whose expression in breast cancer tissues and gastric cancer tissues is markedly down-regulated, and it functions as a tumor suppressor in these cancers [16,17]. However, the role of miR-876-5p in the progression of PCa needs further study.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: MCM3AP-AS1/miR-876-5p/WNT5A axis regulates the proliferation of prostate cancer cells

Wu¹,

Lv²,

Li³

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Although the fact that long non-coding RNA MCM3AP antisense RNA 1 (MCM3AP-AS1) is oncogenic in several cancers is well documented, very few researchers investigate its expression and function in prostate cancer. Methods: Paired prostate cancer samples were selected, and expressions of MCM3AP-AS1, miR-876-5p and WNT5A were examined by qRT-PCR. MCM3AP-AS1 shRNA was transfected into LNCaP and PC-3 cell lines, and then the proliferative activity and apoptosis of cancer cells were detected by CCK-8 assay, EdU assay and flow cytometry analysis, respectively. qRT-PCR and Western blot were used to analyze the changes of miR-876-5p and WNT5A. Luciferase reporter gene assay was employed to determine the regulatory relationship between miR-876-5p and MCM3AP-AS1, miR-876-5p and WNT5A. Results: MCM3AP-AS1 was significantly up-regulated in cancerous tissues of prostate cancer samples, positively correlated with the expression of WNT5A, while negatively related with miR-876-5p. After transfection of MCM3AP-AS1 shRNA into prostate cancer cells, the proliferative ability of cancer cells was signally inhibited, but the apoptosis of cancer cells was increased. MCM3AP-AS1 shRNA could reduce the expression of WNT5A on both mRNA and protein levels. Besides, MCM3AP-AS1 was identified as a sponge of miR-876-5p. WNT5A was validated as a target gene of miR-876-5p. Conclusion: MCM3AP-AS1 is abnormally up-regulated in prostate cancer tissues and can modulate the proliferation and apoptosis of prostate cancer cells, which has the potential to be the "ceRNA" to regulate the expression of WNT5A by targeting miR-876-5p.

show abstract

“…Additionally, we disclosed that SNHG17 had the capacities to bind to miRNAs in astrocytoma cells. Previously, miR-876-5p was reported to inhibit the progression of breast cancer by targeting TFAP2A [ 18 ]. The former study manifested that miR-876-5p regulated cell invasion and metastasis in head and neck squamous cell carcinoma via targeting vimentin [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

SNHG17 drives malignant behaviors in astrocytoma by targeting miR-876-5p/ERLIN2 axis

Hou

2020

BMC Cancer

View full text Add to dashboard Cite

Background Astrocytoma is a common tumor type in primary central nervous system and has a high death rate around the world. Aberrant expression of long non-coding RNAs (lncRNAs) has been introduced by emerging studies to result in the development of diverse cancers. Methods RT-qPCR examined the expression of SNHG17, miR-876-5p and ERLIN2, and western blot evaluated ERLIN2 protein level. RNA pull down and luciferase reporter assays illustrated the relationships between SNHG17 and its downstream molecules. Results SNHG17 was up-regulated in astrocytoma cells. Moreover, SNHG17 silence could repress the proliferation, migration and invasion of astrocytoma cells. Besides, miR-876-5p was selected out as a downstream molecule of SNHG17 in astrocytoma. ERLIN2 was determined to be targeted by miR-876-5p. ERLIN2 mRNA and protein levels were lessened by miR-876-5p overexpression and SNHG17 silence. Additionally, miR-876-5p overexpression decelerated the biological processes of astrocytoma cells, so did ERLIN2 knockdown. More importantly, the impacts of SNHG17 down-regulation on the malignant behaviors of astrocytoma cells were counteracted by overexpressed ERLIN2 or inhibited miR-876-5p. Conclusions SNHG17 could induce the progression of astrocytoma by sponging miR-876-5p to elevate the expression of ERLIN2. This study indicated that SNHG17 has a high potential to be a therapeutic target for astrocytoma.

show abstract

miR‑876‑5p suppresses breast cancer progression through targeting TFAP2A

Cited by 26 publications

References 30 publications

miR‐876 Inhibits EMT and Liver Fibrosis via POSTN to Suppress Metastasis in Hepatocellular Carcinoma

miR‐876 Inhibits EMT and Liver Fibrosis via POSTN to Suppress Metastasis in Hepatocellular Carcinoma

RETRACTED ARTICLE: MCM3AP-AS1/miR-876-5p/WNT5A axis regulates the proliferation of prostate cancer cells

SNHG17 drives malignant behaviors in astrocytoma by targeting miR-876-5p/ERLIN2 axis

Contact Info

Product

Resources

About